| 0880 Low-Crystallinity Carbonated Apatite Solubility Behavior; pH and Solution Strontium Effects | ||
|
D.D. HESLOP1, Y. BI1, A.A. BAIG2, and W.I. HIGUCHI1, 1University of Utah, Salt Lake City, USA, 2The Procter and Gamble Company, Mason, OH, USA Objective: Previous studies (Yan et al., 2001 AADR Abstract #1806) have shown that the stoichiometry of the surface complex governing the metastable equilibrium solubility (MES) of carbonated apatite (CAP) is well-approximated by that of hydroxyapatite for CAP samples of high crystallinity; however, for CAPs having poor crystallinity, there was an apparent decrease in the calcium-to-phosphate (Ca/P) ratio of the surface complex with increasing crystallite microstrain. The purpose of the present study was to examine in more detail this decrease in the Ca/P ratio of the MES governing surface complex for a CAP sample of low crystallinity. Methods: A CAP of low crystallinity (~ 6.4 wt% carbonate, crystallite microstrain parameter = 0.559) was prepared by precipitation/digestion at 50 ºC. MES profiles were determined in a series of 0.1 M acetate buffers with ionic strength = 0.5 at different slurry densities. The pH and strontium/calcium ratios of the dissolution media were varied over wide ranges. All reagents were fluoride–extracted. Results: The MES data were analyzed using models (i.e., surface complex templates) based on the stoichiometries of hydroxyapatite, calcium-deficient (defective) hydroxyapatite, whitlockite, and octacalcium phosphate. Conclusions: It can be concluded from the MES data analysis that when 40% or less of the solution calcium was substituted by strontium, the surface complex can best be described by the calcium-deficient hydroxyapatite stoichiometry (Ca9(HPO4)(PO4)5OH). When the substitution of solution calcium by strontium was 60% or more, a stoichiometry of Ca7Sr2(HPO4)(PO4)5OH best described the experimental data. Supported by NIDCR Grant DE 06569. | ||
| Seq #100 - Enamel and Dentin: Surface Properties and Crystal Formation I 10:15 AM-11:30 AM, Thursday, 11 March 2004 Hawaii Convention Center Exhibit Hall 1-2 | ||
|
Back to the Mineralized Tissue Program
| ||